Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydropiperine SCHEMBL29392462 | 1.00 | TRPV1 (1.00) | TRPV1HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL14200777 | 0.99 | TRPV1 (0.97) | TRPV1HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL9425973 | 0.91 | TRPV1 (0.83) | TRPV1MEN1ALDH1A1LMNATSHR | |
| SCHEMBL9425805 | 0.89 | TRPV1 (0.81) | TRPV1MEN1ALDH1A1LMNATSHR | |
| SCHEMBL15985141 | 0.85 | TRPV1 (0.74) | TRPV1HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL4953724 | 0.83 | TRPV1 (0.71) | TRPV1HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL14200737 | 0.81 | TRPV1 (0.69) | TRPV1HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL9426173 | 0.81 | TRPV1 (0.68) | TRPV1MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL24893059 | 0.80 | TRPV1 (0.66) | TRPV1HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL3815431 | 0.80 | TRPV1 (0.67) | TRPV1MEN1ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120131527-A | An anti-wrinkle skin care composition containing Ganoderma and yeast components | 西沐臻品(上海)生物科技发展有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20240285629-A1 | Combination Therapy for Use in Treating Retroviral Infections | CIPLA LIMITED (IN) | 2024-08-29 | — | — | US | disclosed |
| US-20240109855-A1 | ANTI-QUORUM SENSING, ANTI-BIOFILM, AND INFLAMMATION ATTENUATING COMPOUNDS, COMPOSITIONS, AND METHODS OF USING SAME | B.G. NEGEV TECHNOLOGIES & APPLICATIONS LTD. AT BEN-GURION UNIVERSITY (IL) | 2024-04-04 | — | — | US | disclosed |
| EP-3525825-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING RIFAXIMIN | CIPLA LTD (IN) | 2024-03-20 | — | — | EP | disclosed |
| CN-116869897-A | Red-dispelling repair essence and preparation process thereof | 广东华智化工研究院 | 2023-10-13 | — | — | CN | disclosed |
| CN-110087688-B | Pharmaceutical composition comprising rifaximin | 希普拉有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20230119206-A1 | COMPOSITIONS COMPRISING IBRUTINIB AND AN ALKALOID HAVING ENHANCED BIOAVAILABILITY | CIPLA LIMITED (IN) | 2023-04-20 | — | — | US | disclosed |
| US-20230119206-A1 | COMPOSITIONS COMPRISING IBRUTINIB AND AN ALKALOID HAVING ENHANCED BIOAVAILABILITY | CIPLA LIMITED (IN) | 2023-04-20 | — | — | US | disclosed |
| US-11612612-B2 | Pharmaceutical compositions | CIPLA LIMITED (IN) | 2023-03-28 | — | — | US | disclosed |
| CN-115475194-A | A Chinese medicinal composition foot bath bag for treating loempe and its preparation method | 象记(上海)生物科技有限公司 | 2022-12-16 | — | — | CN | disclosed |
| EP-3413913-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTI-RETROVIRAL DRUG AND A PHARMACOKINETIC ENHANCER | Cipla Limited (IN) | 2018-12-19 | — | — | EP | disclosed |
| WO-2018193470-A1 | COMBINATION THERAPY FOR USE IN TREATING RETROVIRAL INFECTIONS | CIPLA LIMITED (IN) | 2018-10-25 | — | — | WO | disclosed |
| US-20180221427-A1 | TRANSDERMAL FORMULATIONS FOR DELIVERY OF CAPSAICINOIDS | DELIVRA INC. (CA) | 2018-08-09 | — | — | US | disclosed |
| US-20180221427-A1 | TRANSDERMAL FORMULATIONS FOR DELIVERY OF CAPSAICINOIDS | DELIVRA INC. (CA) | 2018-08-09 | — | — | US | disclosed |
| WO-2017138022-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTI-RETROVIRAL DRUG AND A PHARMACOKINETIC ENHANCER | CIPLA LIMITED (IN) | 2017-08-17 | — | — | WO | disclosed |
| US-20170232020-A1 | PHARMACEUTICAL COMPOSITIONS | CIPLA LTD (IN) | 2017-08-17 | — | — | US | disclosed |
| US-20170232020-A1 | PHARMACEUTICAL COMPOSITIONS | CIPLA LTD (IN) | 2017-08-17 | — | — | US | disclosed |
| US-20170232020-A1 | PHARMACEUTICAL COMPOSITIONS | CIPLA LTD (IN) | 2017-08-17 | — | — | US | disclosed |
| WO-2017020125-A1 | TRANSDERMAL FORMULATIONS FOR DELIVERY OF CAPSAICINOIDS | DELIVRA INC. (CA) | 2017-02-09 | — | — | WO | disclosed |
| US-20080146987-A1 | TREATMENT OF A SKIN CONDITION USING A PIPERINE-BASED COMPOSITION IN CONJUNCTION WITH IRRADIATION | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109855-A1 | ANTI-QUORUM SENSING, ANTI-BIOFILM, AND INFLAMMATION ATTENUATING COMPOUNDS, COMPOSITIONS, AND METHODS OF USING SAME | FPR1, FPR2, IL1B | TRPV1 481/4885HDAC1 448/4885HDAC3 449/4885 |
| US-11612612-B2 | Pharmaceutical compositions | HAVCR2, APOB, ABCB11 | TRPV1 4661/4885HDAC1 4219/4885HDAC3 4166/4885 |
| US-20230119206-A1 | COMPOSITIONS COMPRISING IBRUTINIB AND AN ALKALOID HAVING ENHANCED BIOAVAILABILITY | BCL6B, BCL9, BCL6 | TRPV1 4840/4885HDAC1 560/4885HDAC3 925/4885 |
| US-20170232020-A1 | PHARMACEUTICAL COMPOSITIONS | HAVCR2, APOB, ABCB11 | TRPV1 4661/4885HDAC1 4219/4885HDAC3 4166/4885 |
| US-20180221427-A1 | TRANSDERMAL FORMULATIONS FOR DELIVERY OF CAPSAICINOIDS | TRPV1, TRPV4, TRPV2 | TRPV1 1/4885HDAC1 2032/4885HDAC3 1654/4885 |
| US-20240285629-A1 | Combination Therapy for Use in Treating Retroviral Infections | PAICS, HAVCR2, THPO | TRPV1 4819/4885HDAC1 3952/4885HDAC3 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.